What Limits Direct Compression Utility When the Protected Glucofuranose Ring Is Milled to D90 45 µm?

Direct compression of Mono-Acetone-D-Glucose is evaluated on a 10 L V-blender with a pre-blend step at 20 rpm for 8 min; the API is passed through a 0.5 mm sieve before charging. Published compressibility data for this exact pharma-grade material are limited, so tensile strength is screened on a Pharmatron ST50 hardness tester using diametral compression. A milled fraction with D90 below 45 µm and D50 below 15 µm does not automatically produce robust compacts; the non-reducing protected 1,2-diol lowers Maillard-type interactions with amine-bearing excipients but does not guarantee plastic deformation. Tablet tensile strength below 1.5 MPa after compression at 5–9 kN on a 16-station rotary press indicates that silicified microcrystalline cellulose at 35–45 % w/w, crospovidone at 3.0 % w/w, and external lubrication with 0.25 % w/w magnesium stearate are required. Ejection force above 1200 N shows insufficient lubricant coverage. Blend uniformity is checked by stratified sampling at 10 positions after the pre-blend step; relative standard deviation ≤ 5.0 % is targeted before compression.

Compliance for the compressed core follows Ph. Eur. 2.9.5 for mass uniformity and USP <905> for content uniformity with an acceptance value ≤ 15.0. If the final tablet is film-coated, Ph. Eur. 2.9.1 disintegration is performed in 900 mL of water at 37 °C; the release specification must state whether disintegration is completed within 30 min. Residual acetone is controlled under ICH Q3C at ≤ 5000 ppm; if a purified water wetting stage is used prior to compression, vacuum drying at 40 °C under −0.09 MPa reduces free moisture without distilling the acetonide. Final product is an uncoated or film-coated immediate-release tablet.

In automatic capsule filling, the angle of repose of a directly blended formulation containing the milled API above 8 % w/w is measured on a fixed-funnel assembly at 25 °C; values above 40° indicate that tamping-pin machines will not achieve acceptable plug strength. A roller-compacted slug with ribbon density 1.05–1.15 g/cm³, milled through a 0.8 mm screen, gives a plug that survives transport on a Bosch GKF 1500 without splitting. The fill formulation uses lactose monohydrate as primary diluent at 1:2.5 API-to-filler mass ratio, 5 % w/w crospovidone, 0.5 % w/w colloidal silicon dioxide, and 0.7 % w/w sodium stearyl fumarate. Fill weight for a size 1 hydroxypropyl methylcellulose capsule is set at 180 mg; capsule mass variation follows Ph. Eur. 2.9.5, where the deviation limit is 7.5 % because average mass is below 250 mg.

Dissolution testing on the filled capsule uses USP <711> Apparatus 2 at 50 rpm in 900 mL of a pH 6.8 phosphate buffer only if the product-specific monograph assigns that medium; otherwise a bracket at pH 1.2, 4.5, and 6.8 is generated during analytical method development. Because the anomeric centre is blocked by the isopropylidene group, reducing-sugar interaction with gelatin capsule shells is lower than that of unprotected glucose; however, shell cross-linking under humidity stress must still be controlled by storage at ≤ 25 °C and ≤ 60 % RH. The finished capsule is a hard HPMC or gelatin shell containing the API blend.

Granule Growth, Binder Distribution, and Moisture-Related Processing Boundaries in High-Shear Wet Granulation

High-shear wet granulation in a top-drive granulator with a bowl capacity of 10 L uses impeller speed 350 rpm and chopper speed 1500 rpm. A binder solution of povidone K30 at 5 % w/w in purified water is sprayed at 12–15 g/min to control liquid-to-solid ratio between 0.12 and 0.16 w/w; endpoint is identified by stabilisation of impeller torque and amperage for 20 s. The granulation fluid is maintained above pH 5.0 because acidic conditions accelerate hydrolysis of the isopropylidene acetal to free glucose and acetone. Granules are wet-milled through a 1.2 mm screen and dried in a fluid-bed dryer with inlet air at 50–60 °C; product temperature is held below 45 °C until loss on drying reaches 1.0–2.0 % w/w. Dried granules are dry-milled through a 0.8 mm screen and blended with 0.5 % w/w magnesium stearate for 3 min. These values are process-development starting points; published torque endpoint data for this specific API are limited, so a factorial study is required.

Granulated intermediate is compressed into tablets at 8–14 kN or filled into sachets. Particle size distribution is controlled by sieve analysis per Ph. Eur. 2.9.38; at least 90 % passes through 1.0 mm and the retained fraction above 0.125 mm is product-specific. Degradation of the acetonide during granulation is monitored by a related substances method using Ph. Eur. 2.2.29 liquid chromatography; any increase in free acetone content in the granule headspace above the ICH Q3C limit of 5000 ppm indicates process-induced cleavage. Final granule is then used as a tablet intermediate or as a unit-dose sachet.

Injectable presentation imposes a terminal sterilisation decision that depends on the hydrolytic stability of the 1,2-O-isopropylidene group. A formulation containing 25 mg/mL Mono-Acetone-D-Glucose, 0.9 % w/v sodium chloride, and Water for Injection is adjusted with sodium hydroxide to pH 6.5–7.5. Osmolality is measured by freezing point depression and adjusted to 280–320 mOsm/kg; fill volume is 2.15 mL in a 2 mL amber glass vial under Ph. Eur. 2.9.17 extractable volume requirements. The filled solution is filtered through a 0.22 µm PVDF membrane and autoclaved at 121 °C for 15 min only if stress data show no significant increase in free acetone or related reducing sugar; otherwise aseptic processing with double filtration is used. Sterility is assessed by Ph. Eur. 2.6.1 membrane filtration, and bacterial endotoxins are controlled by Ph. Eur. 2.6.14 with a product-specific limit derived from dose and route. Published pH-rate data for this specific API are limited, so forced degradation at pH 4.0 and 7.5 is required before terminal sterilisation is selected.

Particulate matter limits follow USP <788> for large-volume injectables or Ph. Eur. 2.9.19 for small-volume parenterals; light obscuration counting is performed with a syringe sampler. Because the API is not inherently antimicrobial, no bacteriostatic agent is added unless justified by Ph. Eur. 5.1.3 and the product is labelled for multi-dose use. Terminal product is a sterile solution for oral or injectable administration.

When Aqueous Injectable Formulations Must Suppress Isopropylidene Cleavage During Lyophilisation

When terminal autoclaving is not feasible due to acetonide cleavage, a lyophilised sterile powder is prepared. The freeze-drying formulation contains 50 mg API per vial, 2.5 % w/v mannitol as bulking agent, and 0.5 % w/v sucrose if an amorphous stabiliser is required; the solution is filled through a 0.22 µm filter into 10 mL tubing vials at 5 mL fill volume. Freeze-drying microscope and modulated differential scanning calorimetry are used to establish the collapse temperature; published collapse temperature data for this API are limited, so a conservative primary drying shelf temperature of −30 °C and chamber pressure of 100 µbar are selected until the Pirani gauge and capacitance manometer readings converge. Secondary drying is conducted at 25 °C for 4 h to reduce residual moisture to ≤ 1.0 % w/w, measured by Karl Fischer titration per Ph. Eur. 2.5.12.

The lyophilised cake is reconstituted with 2.0 mL Water for Injection to a final concentration of 25 mg/mL; reconstitution time should be less than 60 s with gentle swirling. Container closure integrity is verified by helium leak or dye ingress method per USP <1207>; residual acetone in the lyophilised powder is controlled at ≤ 5000 ppm under ICH Q3C. Final product is a freeze-dried cake for injection.

For oral granules intended for reconstitution, dry mixing followed by top-spray granulation produces a free-flowing intermediate with reduced dust and uniform content. The API is blended with 30 % w/w sucrose, 20 % w/w mannitol, 2 % w/w sodium citrate dihydrate, and 1 % w/w sodium carboxymethylcellulose as a suspending agent; the dry blend is granulated with 5 % w/w povidone solution in 30 % v/v ethanol. Citric acid is excluded because reconstitution would create an acidic microenvironment that accelerates acetonide cleavage. Wet mass is sieved through 1.5 mm and dried at 40 °C to LOD ≤ 1.5 % w/w. The final sachet contains 500 mg API and is reconstituted in 20 mL water; the resulting suspension is used within 30 min to avoid settling of the active. Microbial quality follows Ph. Eur. 5.1.4 for oral liquids made from powders; total aerobic microbial count is ≤ 10³ CFU/g and moulds ≤ 10² CFU/g. Published suspension stability data for this specific API are limited, so a formal stability study at 25 °C and 60 % RH is used to justify the assigned shelf life.